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Anakinra, an interleukin-1 receptor antagonist, increases the morphine analgesic effect
and decreases morphine tolerance development by modulating oxidative stress and
endoplasmic reticulum stress in rats
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Background/aim: Recent studies have shown that inflammation plays a role in morphine analgesia and tolerance development.
Anakinra is a competitive inhibitor of IL-1 receptors and an antiinflammatory protein regulating IL-1β’s biological activity by avoiding
signal transduction. In this study, we aimed to examine the effects of anakinra on morphine analgesia and tolerance.
Materials and methods: In this study, 36 Wistar Albino (230–250 g) male rats were used. Animals were divided into 6 groups: saline
(S), 100 mg/kg anakinra (A), 5mg/kg morphine (M), M+A, morphine tolerance (MT), and MT+A. The resulting analgesic effect was
measured with hot plate and tail-flick analgesia tests. After the analgesia tests, the dorsal root ganglions (DRG) tissues were removed.
Oxidative stress parameters [total antioxidant status (TAS), total oxidant status (TOS)], endoplasmic reticulum (ER) stress, and apoptosis
proteins [E74-like factor 2 (elF-2α), activating transcription factor 4 (ATF-4), C/EBP homologous protein (CHOP), caspase-3, and bcl2-associated X protein (bax)] were measured in DRG tissues.
Results: Anakinra showed an antinociceptive effect when given alone (P < 0.001). In addition, anakinra increased the analgesic effect of
morphine (P < 0.05 to P < 0.001), and also decreased the tolerance to morphine at a significant level (P < 0.05 to P < 0.001). Moreover,
it decreased oxidative stress and ER-stress when given as a single-dose morphine and tolerance induction (P < 0.01 to P < 0.001).
Furthermore, anakinra decreased apoptosis proteins after tolerance development (P < 0.001).
Conclusion: Anakinra has antinociceptive properties, and it increases the analgesic effect of morphine and also prevents tolerance
development. These effects probably occur by the modulation of oxidative stress and ER-stress pathways.
Key words: Anakinra, morphine analgesia, morphine tolerance, oxidative stress, endoplasmic reticulum stress

1. Introduction
Morphine is an opiate receptor agonist and analgesic that
is routinely administered in cases of strong and chronic
pain in clinics. The duration of morphine’s effect is reduced
by the development of tolerance to its antinociceptive
properties. Despite the many studies that have been
made examining the development of opioid tolerance,
it is still unclear as to what exactly causes this. Recent
studies propose that an endogenous proinflammatory
cytokine, especially interleukin 1 beta (IL-1 β), linked to
the regulation of many physiological and pathological
pathways, is involved in morphine analgesia and tolerance
development [1–3].
Glia cells have important roles in facilitating pain by
secreting proinflammatory cytokines, such as IL-1 [4].
However, exogenous IL-1 administration into periphery,

brain, or spinal cord causes hyperalgesia [5]. Systemic or
intrathecal IL-1 neutralizing antibodies treatment or IL1ra treatment decrease or block the hyperalgesia caused by
some inflammatory stimuli [6, 7]. It has been reported that
the deletion of IL-1 receptor types I or of the IL-1 receptor
accessory protein and transgenic overexpression of IL-1
receptor antagonists in the brain and spinal cord, and in
normal mice treated chronically with IL-1ra, show low pain
sensitivity at significant levels [8]. Based on these findings,
it is possible to argue that IL-1 signaling modulates the
sensitivity of pain in basal and inflammatory conditions.
Anakinra is the recombinant form of IL-1ra and is
the first biologic agent designed to modify the biological
immune response of IL-1. Previous studies reported that
it improves the clinical markers of rheumatoid arthritis
(RA) at significant levels. It was approved by the Food
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and Drug Administration (FDA) in 2001 for patients
who had moderate-severe RA [9]. Moreover, anakinra
currently is used for Covid-19 treatment in intensive
care units [10]. However, it has been found that anakinra
has antinociceptive effects on the paclitaxel-induced
neuropathic pain model [11].
Several studies of IL-1 receptor blockers using various
experimental nociceptive models have shown that
they have antinociceptive properties [12,13]. However,
the effect of anakinra on acute nociception, morphine
analgesia, and tolerance development are still unclear. The
purpose of the current study was to examine the possible
involvement of anakinra on nociception, morphine
analgesia, and morphine tolerance development involving
oxidative stress and ER-stress pathways in rats.
2. Materials and methods
2.1. Animals
Wistar Albino rats (230–250 g; n = 6 for each group; in
total 36 rats were used) were acquired from the Animal
Center Laboratory of Cumhuriyet University (Sivas,
Turkey), and kept in standard conditions: a 12-h light and
dark cycle (lights turned on at 08:00 AM) with ad libitum
food and water at constant temperature (22 ± 2 °C). All
of the experiments were performed between 09:00 and
17:00. The animals were handled and the procedures were
carried out in accordance with the National Institute of
Health’s guidelines: “Principles of Animal Laboratory
Care.” The Sivas Cumhuriyet University Animal Ethics
Committee approved the experimental protocols
(Approval No.: 65202830-050.04.04-356).
2.2. Drugs
Morphine sulfate (Sivas Cumhuriyet University Hospital,
Sivas, Turkey) and anakinra (Kineret, 100 mg/0.67 mL
ampule) were dissolved in saline solution. The drugs were
freshly dissolved on trial days. Morphine (5 mg/kg) was
administered subcutaneously (s.c.) and anakinra (100
mg/kg) intraperitoneally (i.p.) before analgesia tests.
2.3. Experimental protocols
Anakinra and morphine’s analgesic effects were evaluated
at 30-min intervals (30, 60, 90, and 120 min) using tailflick and hot-plate antinociception tests. The animals
were separated into 6 groups: saline (S), 100 mg/kg
anakinra (A), 5mg/kg morphine (M), M+A, morphine
tolerance (MT), and MT+A. Saline and anakinra were
administered i.p. and morphine was administered s.c.
at the indicated doses (volume of administration, 1 mL/
kg). After analgesic tests, the animals were sacrificed by
decapitation. The dorsal root ganglions (DRG) tissue
(T12-L5 levels) obtained from the animals underwent
assessments (Figure 1).

2.4. Antinociception tests
Tail-flick test
A standard tail-flick device (May TF 0703 Tail-flick
Unit, Commat, Turkey) was used to measure thermal
nociception. The radiant heat source was focused on the
distal portion of the tail at a distance of 3 cm in each
measurement after the administration of saline or the
study’s drugs. Tail-flick latencies (TFL) were measured
once the saline or the drugs had been administered. The
cut-off latency time was adjusted to 15 s to prevent tissue
injury. The hyperalgesic response in the tail-withdrawal
test is associated with central pain mechanisms.
Hot-plate test
The antinociceptive reaction on the hot-plates is
thought to stem from central and peripheral mechanisms
together. Animals were placed one-by-one on a hot-plate
(May AHP 0603 Analgesic Hot-plate, Commat, Turkey)
at 54 ± 3 °C. The lag until the first paw-licking or jump
reaction to avoid heat was recorded as a pain threshold
indicator. The cut-off time was 30 s to prevent damage to
paws.
2.5. Morphine tolerance induction
To induce morphine tolerance, the rats were selected at
random and treated s.c. with 10 mg/kg morphine twice a
day (09:00 and 17:00) for 5 days. Furthermore, morphine
(10 mg/kg) was applied for 30 min after each anakinra
injection for 5 days in order to determine the impacts of
anakinra (100 mg/kg, i.p.) on morphine tolerance. The
optimal analgesic morphine dose (5 mg/kg, s.c.) was given
on the 6th day without saline or anakinra, and the tailflick and hot-plate tests were measured at 30-min intervals
(30, 60, 90, and 120 min) in order to evaluate the degree
of tolerance.
2.6. DRG tissue homogenate preparation
DRG tissue samples of the animals in cold phosphatebuffer saline solution were homogenized using a
mechanical homogenizer (Analytik Jena Speed Mill Plus,
Jena, Germany) and then centrifuged at 4000 rpm for 10
min at a temperature of 4 ºC. Then, the supernatants were
obtained and stored at –80 °C until biochemical analysis.
A Bradford protein assay kit (Merck, Germany) was used
to determine total protein levels in the samples [14].
2.7. Total antioxidant status (TAS) measurement
TAS concentrations at tissue level were determined with
an automated assay method that was previously developed
by Erel [15] which was based on monitoring the reaction
rate of free radicals by measuring the absorbance of
colored dianisidyl radicals during free radical reactions
starting with hydroxyl radical production in a Fenton
reaction. Antioxidants in the tissue samples should
suppress coloring proportionally to their concentrations
[15]. The outcomes were expressed in micromolar Trolox
equivalents per gram tissue protein (μmol Trolox Eq/g
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Figure 1. Experimental design of the study.

protein).
2.8. Total oxidant status (TOS) measurement
Tissue TOS concentrations were quantified with Erel’s
automated assay method [16]. Because ferrous ion
is oxidized to ferric ion when adequate quantities of
oxidants are available in the medium, the method allows
for quantifying TOS levels by measuring the tissue levels
of ferric ions with the use of xylenol orange. Hydrogen
peroxide was used for the calibration of the assay [16].
The results of the assay were expressed in micromolar
hydrogen peroxide equivalents per gram tissue protein
(μmol H2O2 Eq/g protein).
2.9. Measurement of elF-2α, ATF-4, CHOP, caspase-3,
and bax
The levels of elF-2α, ATF-4, CHOP, caspase-3, and bax
from DRG supernatants were measured using rat ELISA
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commercial kits (Shanghai Sunred Biological Technology,
Shanghai, China). Operation protocols were in line with
the instructions of the manufacturer. In brief, standard
and tissue samples were added in a plate and incubated
for 60 min at 37 °C. After washing, staining solutions were
added and incubated for 15 min at 37 °C. Stop solution
was added and read at 450 nm. Standard curves were
employed in calculating all kits. The variation coefficients
in and between plates were lower than 10%.
2.10. Analgesic tests data analysis
To calculate the maximum antinociceptive effect
percentage (% MPE), tail-flicks and hot-plate lags (which
are in seconds) were converted into an antinociceptive
effectiveness percentage with the following equation: %
MPE = [(post drug latency – baseline latency) / (cut-off
value – Baseline latency)] × 100.
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Figure 2. Effect of anakinra on nociception and morphine analgesia. (a) shows the effect of anakinra on nociception and morphine
analgesia in the tail flick test; (b) shows the effect of anakinra on nociception and morphine analgesia in the hot plate test. Values are
expressed as the means ± SEM of % MPE (n = 6). ***P < 0.001 compared to saline group. #P < 0.05, ##P < 0.01, and ###P < 0.001,
compared to the morphine group.

2.11. Statistical analysis
The results are given as mean ± SEM (standard error of
the mean). The antinociceptive effect was measured, and
the mean % MPEs were calculated. Analysis of variance
(One-Way Anova) and a posthoc Tukey test were used in
analyzing the data. The significance value was set as P <
0.05.
3. Results
3.1. Effect of anakinra on nociception and morphine
analgesia
In order to examine anakinra, analgesic responses were
evaluated for a 100 mg/kg dose of anakinra at 30 min
intervals for 2 h with the analgesia tests. Anakinra showed

antinociceptive effects in comparison with the saline
group at 30, 60, 90, and 120 m in both the tail-flick test
(P < 0.001; Figure 2a) and hot plate test (P < 0.001; Figure
2b). However, the maximum analgesic effect was found at
60 min after 100-mg/kg anakinra administration for the
tail-flick (33.08 ± 1.17) and hot-plate test (31.06 ± 1.06).
The findings demonstrated that anakinra significantly
increased the antinociceptive effect of morphine in the
tail-flick test (P < 0.05 to P < 0.001; Figure 2a) and hot
plate test (P < 0.05 to P < 0.01; Figure 2b) in comparison
with the morphine group. Furthermore, the maximum
increasing effect of anakinra on morphine was detected at
60 min in the tail-flick test (71.99 ± 2.34) and hot-plate test
(54.70 ± 3.33).
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Figure 3. Effect of anakinra on morphine tolerance development. (a) shows the effect of anakinra on morphine tolerance development
in the tail flick test; (b) shows the effect of anakinra on morphine tolerance development in the hot plate test. Values are expressed as the
means ± SEM of % MPE (n = 6). *P < 0.05 and ***P < 0.001, compared to the saline group. ++P < 0.01 and +++P < 0.001, compared to
morphine group. #P < 0.05, ##P < 0.01, and ###P < 0.001, compared to the morphine tolerance group.

3.2. Effect of anakinra on morphine tolerance
development
The morphine group’s % MPE value was statistically higher
than the morphine tolerance group in both the tail-flick
test (P < 0.05 to P < 0.001; Figure 3a) and hot plate test (P
< 0.05 to P < 0.001; Figure 3b). Anakinra with morphine
produced a significantly decreased morphine tolerance
development in the tail-flick test (P < 0.05 to P < 0.001;
Figure 3a) and hot plate test (P < 0.05 to P < 0.001; Figure
3b).
3.3. Effect of anakinra on antioxidant and oxidant
parameters (TAS and TOS levels) in morphine analgesia
and tolerance in DRG
Single-dose morphine administration and tolerance
induction decreased significantly the TAS levels in DRG
compared to saline (P < 0.001; Figure 4a). However,
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anakinra did not ameliorate the effects of morphine and
tolerance (P > 0.05; Figure 4a), and single-dose morphine
increased TOS levels in DRG compared to saline (P < 0.001;
Figure 4b). Nevertheless, anakinra reduced TOS levels in
DRG when combined with morphine compared to single
morphine (P < 0.001; Figure 4b). Moreover, morphine
tolerance increased TOS levels in DRG compared to both
the saline (P <0.001; Figure 4b) and morphine group (P <
0.001; Figure 4b). In the end, anakinra reduced TOS levels
in DRG together with tolerance induction compared to the
morphine tolerance group (P < 0.001; Figure 4b).
3.4. Effect of anakinra on ER-stress proteins (elF-2α,
ATF-4 and CHOP levels) in morphine analgesia and
tolerance in DRG
The single-dose morphine raised elF-2α levels in DRG
compared to saline (P < 0.001; Figure 5a). However,
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Figure 4. Effect of anakinra on antioxidant and oxidant parameters (TAS and TOS levels) in morphine analgesia and tolerance in DRG
(a) shows the effect of anakinra on TAS levels in morphine analgesia and tolerance in DRG; (b) shows the effect of anakinra on TOS
levels in morphine analgesia and tolerance in DRG. Values are expressed as the means ± SEM of % MPE (n = 6). ***P < 0.001, compared
to the saline group. +++P < 0.001, compared to the morphine group. ###P < 0.001, compared to the morphine tolerance group.

anakinra reduced elF-2α levels in DRG when combined
with morphine compared to single morphine (P < 0.001;
Figure 5a). In addition, morphine tolerance increased elF2α levels in DRG compared to both the saline (P < 0.001;
Figure 5a) and single morphine (P < 0.001; Figure 5a).
However, anakinra reduced elF-2α levels in DRG together
with tolerance induction compared to the morphine
tolerance group (P < 0.001; Figure 5a).
Single morphine increased ATF-4 levels in DRG
compared with saline (P < 0.001; Figure 5b). However,
anakinra decreased ATF-4 levels in DRG combined with
morphine compared to single-dose morphine (P < 0.001;
Figure 5b). Furthermore, morphine tolerance raised ATF4 levels in DRG compared to saline (P < 0.001; Figure

5b) and single-dose morphine administration (P < 0.001;
Figure 5b). Nevertheless, anakinra reduced ATF-4 levels
in DRG when given together with tolerance development
compared to the morphine tolerance group (P < 0.001;
Figure 5b).
Single-dose morphine raised CHOP levels in DRG
compared to saline (P < 0.01; Figure 5c). Although
anakinra combined with morphine reduced CHOP levels
in DRG, this was not at a significant level (P > 0.05; Figure
5c). Also, morphine tolerance increased CHOP levels in
DRG compared to both saline (P < 0.001; Figure 5c) and
single morphine (P < 0.001; Figure 5c). However, anakinra
reduced CHOP levels in DRG together with tolerance
induction compared to the morphine tolerance group (P
< 0.001; Figure 5c).
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Figure 5. Effect of anakinra on ER-stress proteins (elF-2α, ATF-4, and CHOP levels) in morphine analgesia and tolerance in DRG (a)
shows the effect of anakinra on elF-2α levels in morphine analgesia and tolerance in DRG; (b) shows the effect of anakinra on ATF-4
levels in morphine analgesia and tolerance in DRG; (c) shows the effect of anakinra on CHOP levels in morphine analgesia and tolerance
in DRG. Values are expressed as the means ± SEM of % MPE (n = 6). **P < 0.01 and ***P < 0.001, compared to the saline group. +++P
< 0.001, compared to the morphine group. ###P < 0.001, compared to the morphine tolerance group.
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Figure 6. Effect of anakinra on apoptosis (caspase-3 and bax levels) in morphine analgesia and tolerance in DRG. (a) effect of anakinra
on caspase-3 levels in morphine analgesia and tolerance in DRG; (b) shows the effect of anakinra on bax levels in morphine analgesia
and tolerance in DRG. Values are expressed as the means ± SEM of % MPE (n = 6). ***P < 0.001, compared to the saline group. +++P <
0.001, compared to the morphine group. ###P < 0.001, compared to the morphine tolerance group.

3.5. Effect of anakinra on apoptosis (caspase-3 and bax
levels) in morphine analgesia and tolerance in DRG
Single morphine administration did not change caspase-3
levels in DRG compared to saline (P > 0.05; Figure 6a).
However, morphine tolerance raised caspase-3 levels in
DRG compared to saline (P < 0.001; Figure 6a) and also
single-dose morphine administration (P < 0.001; Figure
6a). Furthermore, anakinra reduced caspase-3 levels in
DRG when given together with tolerance development
compared to the morphine tolerance group (P < 0.001;
Figure 6a).
Single-dose morphine did not also alter bax levels
in DRG compared to saline (P > 0.05; Figure 6b).
Nevertheless, morphine tolerance increased bax levels
in DRG compared to both the saline (P < 0.001; Figure

6b) and single morphine groups (P < 0.001; Figure 6b).
On the other hand, anakinra reduced bax levels in DRG
given together with tolerance induction compared to the
morphine tolerance group (P < 0.001; Figure 6b).
4. Discussion
In this study, we investigated the impacts of anakinra on
nociception, morphine analgesia, tolerance development,
and possible mechanisms. An IL-1 receptor antagonist,
anakinra showed a marked antinociceptive effect,
enhanced morphine analgesia, and also decreased
morphine tolerance development. The results are in
line with previous studies reporting that blockage of the
IL-1 receptor has an antinociceptive effect and increases
morphine analgesia and tolerance development [1,11].
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Moreover, some previous studies have suggested that
mice strains characterized with high endogenous IL-1
(beige-J mutation and diabetic mice) levels showed
resistance to morphine analgesia. These results are
in line with the report of another study arguing that
an intracerebroventricular-neutral dose of IL-1b
administration eliminated morphine’s analgesic effect in
diabetic and control mice [17]. Furthermore, some studies
have shown morphine-induced IL-1 production. Chronic
in vivo morphine administration to nerve-transected
and control rats activated spinal glia, upregulated spinal
mRNA, and protein levels of proinflammatory cytokines
(especially IL-1b and IL-6) [18]. Chronic morphine
also improved IL-1’s mRNA expression in peritoneal
macrophages [19]. Morphine exposure activated IL-1b
synthesis by macrophages under in vitro conditions [20].
Corroborating the present findings, a study reported that
intrathecal IL-1ra potentiated acute morphine analgesia [2].
Moreover, it has been suggested that the blocking of acute
morphine activates satellite glial cells, upregulating IL-1b
in DRG in mice with matrix metalloprotease-9 [21]. Taken
together, these studies show that both chronic and acute
morphine are related to an increase in proinflammatory
cytokines in the nervous system, and this is one of the
reasons why both types restrain morphine analgesia and
trigger morphine tolerance development. Therefore, the
administration of anakinra increases morphine analgesia
and reduces morphine tolerance development by blocking
the engagement of IL-1 cytokine to its receptor.
Systemic morphine use ended in oxidative stress with a
reduction in decreased glutathione levels, in lipid peroxide
malondialdehyde levels, and peroxynitrite production
in continuous use, which occurred simultaneously with
tolerance and dependence development. Antioxidants,
such as thymoquinone and those that target peroxynitrite
formation, reversed biochemical changes and morphine
tolerance and dependence [22,23]. In this study, it was
found that single-dose morphine and also morphine
chronic administration for development tolerance
decreases antioxidant status (TAS) in DRG, and this
is consistent with previous studies. However, anakinra
altered TAS levels neither together with single morphine
nor tolerance in DRG. It may show that morphine use
suppresses the antioxidant system, and this may be related
to development tolerance. Furthermore, it also was also
shown that single-dose morphine and chronic morphine
administration cause oxidative stress (TOS) in DRG in
this study. Moreover, chronic morphine administration
increased TOS levels more in single-dose than in DRG. This
may be associated with tolerance development. However,
anakinra alleviated these morphine-related effects.
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Endoplasmic reticulum stress was associated with
participation in neuropathic pain mechanisms [24,25] and
inflammatory pain [26]. In addition, ER stress activation
was found in the peripheral nervous system of diabetic
nephropathy rats [24]. Moreover, a few recent studies have
reported that ER stress has a role in morphine analgesia
and tolerance mechanisms [27,28]. It has also been found
that PERK/eIF2a ER stress pathway activation increased
after tolerance in the spinal cord [28]. In this study, it was
found that ER stress proteins (elF-2α, ATF-4 and CHOP)
increased in single-dose morphine and chronic morphine
administration in DRG. However, chronic morphine
administration increased ER stress proteins more than
single-dose morphine in DRG. At the same time, anakinra
reversed the effects of morphine.
Previous studies have reported that morphine
tolerance is implicated in neuronal apoptosis by mediating
some cellular mechanisms such as oxidative stress and ER
stress [29,30]. Our findings have indicated that morphine
tolerance induced apoptosis in DRG by increasing
caspase-3 and bax in DRG. This is consistent with a
previous study. However, the acute administration of single
morphine did not activate apoptosis despite increasing
oxidative stress and ER stress. It may be related to the fact
that there is a threshold for apoptosis in DRG. Otherwise,
anakinra decreased apoptosis when giving tolerance by
decreasing caspase-3 and bax in DRG.
5. Conclusion
Findings from this study showed that anakinra has
antinociceptive properties, increases morphine analgesic
effect, and also prevents tolerance development against
chronic administration of morphine, possibly through
inhibition of proinflammatory IL-1 cytokine adhesion to
its receptor, blocking of oxidative stress, and suppressing
ER stress in DRG. Thus, anakinra might be a potential
therapeutic agent in morphine tolerance development
management in clinical environments, especially in
intensive care units.
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